Matthew Snape is a paediatrician who joined Moderna in 2022 to lead their Paediatric and Maternal Clinical Development team.

Prior to this he worked as the NIHR Oxford BRC Consultant in Vaccinology and Pediatrics at the Oxford Vaccine Group (University of Oxford) and the Oxford Children’s Hospital.

Research interests while at the Oxford Vaccine Group included leading phase 1 to 4 studies on vaccines against pathogens such as RSV, Ebola virus, Influenza, Pneumococcus and Meningococcus. From 2017 to 2022 he led the NIHR funded National Immunisation Schedule Evaluation Consortium (NISEC), tasked with conducting research studies of relevance to UK immunisation policy. In this role he lead the ‘COM-COV’ trials studying heterologous COVID-19 vaccine schedules

Matthew Snape is originally from Melbourne, Australia, where he trained in Paediatrics at the Royal Children’s Hospital.